1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
HUTCHMED (China) Limited

HUTCHMED (China) Limited

HMDCF
HUTCHMED (China) LimitedUS flagOther OTC
2.16
USD
- -
- -
1.86BMarket Cap
HUTCHMED (China) Limited
HMDCF
(Other OTC)

Recent

price

2.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.26
0.32
0.04
0.09
0.17
0.33
0.36
0.39
0.32
0.31
0.33
0.45
0.5
0.99
0.74
0.64
Revenue per Share
-0.01
- -
0.01
0.01
-0.01
0.01
0.02
-0.04
-0.11
-0.16
-0.18
-0.25
-0.43
0.12
0.04
0.53
Basic EPS, GAAP
-0.06
- -
-0.02
- -
0.01
-0.02
-0.02
-0.02
-0.06
-0.13
-0.12
-0.28
-0.36
0.22
-0.02
-0.1
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.08
-0.08
-0.07
-0.04
-0.09
-0.06
-0.03
-0.07
-0.18
-0.34
-0.49
-0.66
-1.04
-0.92
-0.87
-0.34
Book Value per Share
0.1
0.1
0.16
0.2
0.18
0.18
0.34
0.78
0.62
0.46
0.74
1.31
0.75
0.87
0.9
1.45
Tangible Book Value per Share
515
517
519
521
526
547
597
617
664
666
698
793
847
850
855
858
Basic Weighted Avg Shares
135
165
22
46
87
178
216
241
214
205
228
356
426
838
630
549
Sales/Revenue/Turnover
-1.93
4
-77.95
-2.28
-20.91
-5.48
-21.61
-22.1
-43.27
-71.45
-86.27
-92.1
-95.27
2.57
-6.44
-6.51
Operating Margin (%)
5
5
2
1
1
2
2
3
4
5
6
7
9
8
12
13
Depreciation Expense
-7
1
4
6
-7
8
12
-27
-75
-106
-126
-195
-361
101
38
457
Net Income, GAAP
- -
50.48
9.4
10.43
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.73
- -
12.76
Effective Tax Rate (%)
-5.1
0.43
16.27
12.87
-8.37
4.49
5.41
-11.08
-34.94
-51.75
-55.15
-54.66
-84.62
12.03
5.99
83.3
Profit Margin (%)
40
52
9
-11
15
8
72
328
285
204
372
900
486
694
690
1,252
Working Capital
- -
- -
27
- -
27
27
27
- -
27
30
33
7
23
51
64
70
LT Debt
69
77
82
105
98
102
204
485
412
313
519
1,040
637
743
772
1,251
Total Equity
- -
3.22
-13.83
-0.68
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.65
- -
-2.81
Return on Invested Capital (%)
- -
0.05
72.59
20.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
-13.34
- -
-111.25
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.82%
28.85%
62.11%
Free Cash Flow
65.28%
68.03%
409.32%
Net Income, GAAP
101.86%
212.15%
1,111.03%
Sales/Revenue/Turnover
16.33%
26.94%
-12.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
838
2024
- -
- -
- -
- -
630
2025
- -
- -
- -
- -
549

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.12
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.53

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Pharmanutra S.p.A. (PHN.MI)
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ)
Mangalam Drugs & Organics Limited (MANGALAM.NS)
Ironwood Pharmaceuticals, Inc. (IRWD)
Delta 9 Cannabis Inc. (DLTNF)
JW Pharmaceutical Corporation (001065.KS)
Business
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) is an innovative commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. Founded in 2000 and headquartered in Hong Kong with primary operations in mainland China, the company offers marketed products including Elunate (fruquintinib), a selective oral VEGFR inhibitor for metastatic colorectal cancer; Orpathys (savolitinib), a selective oral MET inhibitor for non-small cell lung cancer with MET exon 14 skipping mutations; Sulanda (surufatinib), an angio-immuno kinase inhibitor targeting VEGFR, FGFR, and CSF-1R for advanced neuroendocrine tumors; and Fruzaqla (fruquintinib), approved in the US, Europe, and Japan for metastatic colorectal cancer. It maintains a robust pipeline of novel drug candidates from its in-house discovery engine, emphasizing oncology and immunology treatments with global market potential, and operates a profitable commercial platform for prescription drugs and consumer health products primarily in China while expanding internationally through partnerships. Recent developments include Takeda’s US launch of Fruzaqla generating initial sales recognition, collaboration progress with Inmagene on IMG-007 (anti-OX40 antibody) and IMG-004 (BTK inhibitor) yielding a 7.5% equity stake for HUTCHMED, updated 2025 revenue guidance of $270-350 million for oncology/immunology reflecting milestone phasing, and strategic emphasis on partnering with multinational firms like AstraZeneca, Lilly, and Takeda amid portfolio expansion toward six or seven marketed oncology drugs in China by year-end.